A case of ST elevation myocardial infarction precipitated by methylphenidate therapy for gait freeze

Parkinson's disease affects 1% of the population older than 60 years. Motor symptoms can be difficult to treat in end‐stage disease, leading to the use of therapies with less favourable adverse effect profiles.

[1]  L. Defebvre,et al.  Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial , 2012, The Lancet Neurology.

[2]  W. Bilker,et al.  Methylphenidate and risk of serious cardiovascular events in adults. , 2012, The American journal of psychiatry.

[3]  P. Foley.  Methylphenidate for gait impairment in Parkinson disease: A randomized clinical trial , 2011, Neurology.

[4]  M. Hallett,et al.  Freezing of gait: moving forward on a mysterious clinical phenomenon , 2011, The Lancet Neurology.

[5]  L. Rohde,et al.  Catechol-O-Methyltransferase Valine158Methionine Polymorphism Moderates Methylphenidate Effects on Oppositional Symptoms in Boys with Attention-Deficit/Hyperactivity Disorder , 2011, Biological Psychiatry.

[6]  A. Espay,et al.  Methylphenidate for gait impairment in Parkinson disease , 2011, Neurology.

[7]  B. Bloem,et al.  Postural instability in Parkinson’s disease: the adrenergic hypothesis and the locus coeruleus , 2009, Expert review of neurotherapeutics.

[8]  J. Nutt,et al.  Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial. , 2007, Archives of neurology.

[9]  L. Defebvre,et al.  Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson’s disease , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[10]  S. Nissen.  ADHD drugs and cardiovascular risk. , 2006, The New England journal of medicine.

[11]  J. Biederman,et al.  Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. , 2005, The Journal of clinical psychiatry.

[12]  D. Greenblatt,et al.  A method for estimating the probability of adverse drug reactions , 1981, Clinical pharmacology and therapeutics.

[13]  Arnaud Delval,et al.  Methylphenidate , 2012, CNS Drugs.

[14]  Katunina Ea,et al.  [Epidemiology of Parkinson's disease]. , 2013, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[15]  James R. Thompson,et al.  Acute myocardial infarction related to methylphenidate for adult attention deficit disorder. , 2010, The Journal of emergency medicine.